



**Translational Research E- Conference
ACUTE LYMPHOBLASTIC LEUKAEMIA**

May 7-9, 2021

Chairpersons: Jan Cools (Leuven), Hervé Dombret (Paris), Adele Fielding (London), Mark Litzow (Rochester)

Friday, May 7th, 2021

13:50-14:00 Welcome : The 4 Chairpersons

SESSION I – BIOLOGY OF B-CELL PRECURSOR ALL

Chairs: Jan Cools (Leuven) & Adolfo Ferrando (New York)

14:00-14:05	Introduction	Chair
14:05-14:25	<u>Keynote</u> : HOX Gene Deregulation in ALL	Scott Armstrong (Boston)
14:25-14:40	Transcriptional Landscape of B-cell Precursor ALL	Henrik Lilljebjörn (Lund)
14:40-14:55	Myeloid Switch of B-cell Precursor ALL Subtypes	Ester Mejstrikova (Prague)
14:55-15:10	Targeting Novel B-cell progenitor ALL Subtypes	Charles Mullighan (Memphis)
15:10-15:17	Selected brief oral communication	
15:17-15:47	<i>Panel discussion</i>	

SESSION II – BIOLOGY OF T-CELL ALL

Chairs: Charles Mullighan (Memphis) & Scott Armstrong (Boston)

15:47-15:52	Introduction	Chair
15:52-16:07	Molecular Mechanisms of T-ALL	Adolfo Ferrando (New York)
16:07-16:22	Aberrant Signaling in T-cell ALL	Jan Cools (Leuven)
16:22-16:37	Targeting CD3 in T-ALL	Jacques Ghysdael (Orsay)
16:37-16:44	Selected brief oral communication	Speaker
16:44-17:14	<i>Panel discussion</i>	
17:14-17:25	Break	

SESSION III – MINIMAL RESIDUAL DISEASE MONITORING

Chairs: Sabina Chiaretti (Rome) & Selina Luger (Philadelphia)

17:25-17:30	Introduction	Chair
17:30-17:45	Euro MRD Activities	Beat Schäfer (Zurich)
17:45-18:00	Which MRD for ALL Treatment Stratification?	Monika Brüggeman (Kiel)
18:00-18:15	IG-TCR <i>versus</i> BCR-ABL1 MRD in Ph+ ALL	Lenka Hovorkova (Prague)
18:15-18:22	Selected brief oral communication	Speaker
18:22-18:52	<i>Panel discussion (S. Luger: 12h40)</i>	
18:52	Mentored Poster Walk #1 2 Poster Leaders Biology 2 Poster Leaders Clinical	

Saturday, May 8th, 2021

10:30-11:30 3 Simultaneous Meet the Expert sessions (non clinical)
- CAR T-cells : Practical Issues: Nicolas Boissel
- Role of HSCT in Ph+ ALL: Oliver Ottman
- Monitoring L-asparaginase Efficacy in ALL Patients: Mathilde Hunault

11:30-12:30 Mentored Poster Walk #2
2 Poster Leaders Biology
2 Poster Leaders Clinical

12:30-13:30 Possible slot for a satellite symposium

13:30-14:30 Lunch

SESSION IV – INDIVIDUALIZED MANAGEMENT OF ALL

Chairs: Nicola Gokbüget (Frankfurt) & Elizabeth Raetz (New York)

14:30-14:35	Introduction	Chair
14:35-14:50	Treatment Issues in Teenagers and Young Adults ALL	Rachael Hough (London)
14:50-15:05	Treatment Issues in Older ALL	Selina Luger (Philadelphia)
15:05-15:20	Management of Relapsed ALL	Elias Jabbour (Houston)
15:20-15:27	Selected brief oral communication	Speaker
15:27-15:57	<i>Panel discussion</i>	

SESSION V – NEW ADVANCES IN ALL

Chairs: Hervé Dombret (Paris) & Shannon Maude (Philadelphia)

15:57-16:02	Introduction	Chair
16:02-16:17	The Critical Role of Microenvironment in ALL	Adele Fielding (London)
16:17-16:32	TKI Use in Ph+/Ph-like Diseases	Stephen Hunger (Philadelphia)*
16:32-16:47	New ALL Drugs	Matthew Wieduwilt (San Diego)
16:47-16:54	Selected brief oral communication	Speaker
16:54-17:25	<i>Panel discussion</i>	

17:25-17:35 Break

SESSION VI – CAR T-CELLS & ALLOGENEIC HSCT

Chairs: Adele Fielding (London) & Nicolas Boissel (Paris)

17:35-17:40	Introduction	Chair
17:40-17:55	Outcome of ALL Patients Treated with CAR T-cells	Shannon Maude (Philadelphia)
17:55-18:10	New CARs for B-cell Precursor ALL	Claire Roddie (London)
18:10-18:25	Post-transplant Interventions	David Marks (Bristol)
18:25-18:32	Brief Oral Communication	Speaker
18:32-19:00	<i>Panel discussion</i>	

SESSION VII – FRONTLINE INCORPORATION OF BiTEs and ADCs

Chairs: Mark Litzow (Rochester) & Anjali Advani (Cleveland)

19:00-19:05	Introduction	Chair
19:05-19:25	<u>Keynote</u> : The MD Anderson Cancer Center Experience	Hagop Kantarjian (Houston)
19:25-19:40	Adult ALL Trials	Nicola Gökbuget (Frankfurt)
19:40-19:55	Childhood ALL Trials	Lia Gore (Aurora)
19:55-20:10	Frontline Chemo-free Regimens in Ph+ ALL	Sabina Chiaretti (Rome)
20:10-20:40	<i>Panel discussion</i>	

Sunday, May 9th, 2021

13:00-14:00 3 Simultaneous Breakfast Meet the Expert Sessions (Clinical)
- **Monika Brüggeman: MRD Issues**
- **David Marks: Allogenic STC in ALL: Open issues**
- **Nicola Gökbuget: Optimal use of BiTEs**

14:00-14:20 Keynote: Management of T-LL Patients

Dieter Hoelzer (Frankfurt)

SESSION VIII – T-CELL ALL and LYMPHOBLASTIC LYMPHOMA

Chairs: Anjali Advani (Cleveland) & David Marks (Bristol)

14:20-14:25 Introduction

Chair

14:25-14:40 Risk Factors in T-ALL

Elizabeth Raetz (New York)

14:40-14:55 Should T-LL and T-ALLs be treated on the same protocols?

Elisabeth Macintyre (Paris)

14:55-15:10 Novel Therapies for T-ALL/LL

Anjali Advani (Cleveland)

15:10-15:17 **Brief Oral Communication**

Speaker

15:17-15:47 *Panel discussion*

15:47-16:00 Break

SESSION IX – Ph AND Ph-LIKE ALL

Chairs: Oliver Ottman (Cardiff) & Sabina Chiaretti (Rome)

16:00-16:05 Introduction

Chair

16:05-16:20 Which TKI-Chemo-Transplant Cocktail for Ph+ ALL?

Yves Chalandon (Geneve)

16:20-16:35 Next generation TKIs for Ph+ ALL

Nicholas Short (Houston)

16:35-16:50 Ph-like ALL Patient Management

Sarah Tasian (Philadelphia)

16:50-16:57 **Brief Oral Communication**

Speaker

16:57-17:30 *Panel discussion*

17:30-17:45 Closing Remarks: Mark Litzow or Hervé Dombret

MEETING CLOSURE : The 4 Chairpersons

(* pending confirmation)